REG - Genedrive PLC - CYP2C19-ID Kit adopted for routine clinical use

GenedriveAnnouncement

14/03/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250314:nRSN6193Aa&default-theme=true

RNS Number : 6193A  Genedrive PLC  14 March 2025

genedrive plc

("genedrive" or the "Company")

 

North West Anglia Foundation NHS Trusts' Peterborough City Hospital implements
the Genedrive® CYP2C19-ID Kit for routine clinical use

 

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company,
is pleased to announce that the Genedrive® CYP2C19-ID Kit has been
implemented into the Hyperacute and Acute Stroke Units of Peterborough City
Hospital Acute Stroke Centre for routine clinical use.

Hyperacute Stroke units ("HASUs") and Acute Stroke Units ("AUs") are part of
the UK's Integrated Stroke Delivery Network, where care typically covers the
first 72 hours after admission, with the aim that every patient with acute
stroke should gain rapid access to a stroke unit in under 4 hours, and receive
an early multidisciplinary assessment(1).

Peterborough City Hospital provides care to approximately 900 stroke patients
per annum and is part of North West Anglia Foundation NHS Trust Acute Stroke
Centre. The implementation seeks initially to provide genotype-guided
optimisation of prescription of antiplatelet drugs to patients presenting with
recurrent ischaemic strokes or transient ischaemic attack as well as to young
stroke patients aged 18 to 55 within the North West Anglia NHS Foundation
Trust Acute Stroke Centre region.

 

Dr Gino Miele, CEO of genedrive plc, said: "We are delighted with the
successful implementation of our rapid CYP2C19 genotyping technology in
Peterborough City Hospital, this represents a further milestone in our
commercialisation strategy, which continues to strengthen our rapid
pharmacogenetic positioning strategy in emergency care more broadly.  We look
forward to growing implementation of our CYP2C19 test in the UK NHS and
internationally, enabling significant improvement of patient outcomes whilst
also offering substantial resource savings to pressured healthcare systems."

 

Professor Radim Licenik, Consultant Stroke Physician, Clinical Lead for Stroke
Service and President of the Society of Czech & Slovak Doctors in the
United Kingdom, said: "We are delighted to bring the benefit of this novel
technology to Stroke patients in our region. Effective clinical management of
neurologic stroke relies in part on optimising the efficacy of anti-platelets
prescribed, and within a timeframe that is served only by rapid genetic
testing technologies such as this. The implementation will help us to
formulate a personalised optimal treatment plan for our stroke patients, that
we hope will prevent future strokes and save lives."

 

1.
https://www.england.nhs.uk/wp-content/uploads/2021/05/stroke-service-model-may-2021.pdf
(https://www.england.nhs.uk/wp-content/uploads/2021/05/stroke-service-model-may-2021.pdf)

 

For further details please contact:

 

 genedrive plc                                     +44 (0)161 989 0245
 Gino Miele: CEO / Russ Shaw: CFO

 Peel Hunt LLP (Nominated Adviser and Broker)      +44 (0)20 7418 8900
 James Steel

 Walbrook PR Ltd (Media & Investor Relations)      +44 (0)20 7933 8780 or genedrive@walbrookpr.com
                                                   (mailto:genedrive@walbrookpr.com)
 Anna Dunphy                                       +44 (0)7876 741 001

 

 

About genedrive plc (http://www.genedriveplc.com).

genedrive plc is a pharmacogenetic testing company developing and
commercialising a low cost, rapid, versatile and simple to use point of need
pharmacogenetic platform for the diagnosis of genetic variants. This helps
clinicians to quickly access key genetic information that will aid them make
the right choices over the right medicine or dosage to use for an effective
treatment, particularly important in time-critical emergency care healthcare
paradigms. Based in the UK, the Company is at the forefront of Point of Care
pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on
how your individual genetics impact a medicines ability to work for you.
Therefore, by using pharmacogenetics, medicine choices can be personalised,
made safer and more effective. The Company has launched its two flagship
products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit,
both developed and validated in collaboration with NHS partners and deployed
on its point of care thermocycler platform. Both tests are single-use
disposable cartridges which are ambient temperature stable, circumventing the
requirement for cold chain logistics. The Directors believe the Genedrive®
MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on
antibiotic use in neonatal intensive care units within 26 minutes, ensuring
vital care is delivered, avoiding adverse effects potentially otherwise
encountered and with no negative impact on the patient care pathway. Its
CYP2C19 ID Kit which has no comparably positioned competitor currently allows
clinicians to make a decision on the use of Clopidogrel in stroke patients in
70 minutes, ensuring that patients who are unlikely to benefit from or suffer
adverse effects from Clopidogrel receive an alternative antiplatelet
therapeutic in a timely manner, ultimately improving outcomes. Both tests have
undergone review by the National Institute for Health and Care Clinical
Excellence ("NICE") and have been recommended for use in the UK NHS.  The
Company has a clear commercial strategy focused on accelerating growth through
maximising in-market sales, geographic and portfolio expansion and strategic
M&A, and operates out of its facilities in Manchester.

 

The Company has a clear commercial strategy focused on accelerating growth
through maximising in-market sales, geographic and portfolio expansion and
strategic M&A, and operates out of its facilities in Manchester.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUOANRVNUOAAR